For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240621:nRSU2919Ta&default-theme=true
RNS Number : 2919T Argent Biopharma Limited 21 June 2024
21 June 2024
Argent BioPharma Ltd.
(Argent BioPharma or the Company)
Appointment of UK Corporate Broker
Argent BioPharma, an innovative multidisciplinary drug discovery company
within the biopharmaceutical sector, is pleased to announce the appointment of
Shore Capital Stockbrokers Limited as the Company's UK Corporate Broker with
immediate effect.
Roby Zomer, CEO & Managing Director of Argent BioPharma, commented:
"We are delighted to announce the appointment of Shore Capital as our new UK
Corporate Broker. This is a further step in our comprehensive restructuring
process to position Argent BioPharma in pioneering drug discovery within the
biopharmaceutical sector, supported by the strengthening of our management
team and advisory board. We look forward to working with the team at Shore
Capital as we seek to enhance our visibility and engagement with investors."
-Ends-
Authorised for release by the board of directors, for further information
please contact:
Argent BioPharma Argent BioPharma
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@argentbiopharma.co (mailto:info@argentbiopharma.co) m info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m
UK IR/PR Advisers UK Corporate Broker
IFC Advisory Shore Capital
Graham Herring / Tim Metcalfe / Zach Cohen Toby Gibbs / James Thomas / Lucy Bowden
+44 203 934 6630 +44 (0)207 408 4090
argentbiopharma@investor-focus.co.uk
(mailto:argentbiopharma@investor-focus.co.uk)
About Argent BioPharma
Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; ORCQB: RGTLF) is
a Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to
providing accessible medical treatments for unmet medical needs, to bridge the
gap where medical solutions currently fall short. The Group focuses on the
Multidisciplinary method with Nanotechnology, developing multi-target
therapies for comprehensive disease management, especially relating to the
Central nervous system ("CNS")
(https://www.kenhub.com/en/library/anatomy/the-central-nervous-system) and
Immunology treatments.
About Shore Capital
Shore Capital is an independent securities business offering investment
banking, research, sales and trading services to companies on both the Main
Market and AIM.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END APPFLFVRRTIIFIS